Uzbekistan

Uzbekistan Estimates Cost of Combating Antibiotic Resistance at $860,000

Uzbekistan Estimates Cost of Combating Antibiotic Resistance at $860,000
Uzbekistan Estimates Cost of Combating Antibiotic Resistance at $860,000 / Photo: ADB..

Tashkent, Uzbekistan (UzDaily.uz) — Uzbekistan has estimated the cost of measures to combat antimicrobial resistance under its National Action Plan for Health Security for 2024–2028 at $860,000, representing approximately 10% of the plan's total estimated cost. Meanwhile, an international assessment conducted in 2022 identified limited national capacities in four key areas of antimicrobial resistance control. Representatives of Uzbekistan discussed the development of laboratory surveillance, existing challenges, and priorities for the coming years at an international conference in Astana on November 19.

Uzbekistan plans to strengthen its response to antimicrobial resistance by expanding laboratory surveillance, monitoring antibiotic use, and improving cooperation among healthcare, veterinary, and environmental institutions.

These priorities are outlined in the National Action Plan for Health Security (NAPHS) for 2024–2028.

Representatives of the Ministry of Health, the Committee for Sanitary and Epidemiological Welfare and Public Health, and the Committee for Food Safety presented the country's achievements and remaining challenges at an international conference on antimicrobial resistance in Astana.

$860,000 Estimated for Combating Antimicrobial Resistance

The total estimated cost of activities under Uzbekistan's National Action Plan for Health Security for 2024–2028 amounts to $8.4 million.

The plan covers 19 technical areas, at least 72 priorities, and more than 300 activities.

Approximately $860,000, or around 10% of the total estimated cost, is allocated in the plan to measures addressing antimicrobial resistance.

The largest component, estimated at $520,000, covers the national antimicrobial resistance programme, intersectoral coordination, and implementation of the One Health approach.

A further $180,000 is planned for developing antimicrobial resistance surveillance in humans and animals, including harmonized protocols and a veterinary reference laboratory.

Another $150,000 is earmarked for monitoring antimicrobial prescribing and consumption, introducing the WHO AWaRe classification, and implementing antimicrobial stewardship programmes.

An additional $10,000 is intended for the analysis of antimicrobial resistance projects.

The plan also provides for annual reporting to the international CAESAR and GLASS surveillance systems, although no separate budget is specified for this activity.

Importantly, the $860,000 figure represents the estimated cost of planned measures. The presentation does not confirm that the entire amount has already been funded or spent.

International Assessment Identified Gaps in Surveillance Capacity

An important reference point for strengthening Uzbekistan's national system was the Joint External Evaluation (JEE), conducted on May 16–20, 2022.

The evaluation used a five-point scale to assess the country's capacities in relevant technical areas.

According to the findings presented, intersectoral coordination on antimicrobial resistance received a score of 2 out of 5.

The same score was assigned to antimicrobial resistance surveillance, infection prevention and control, and antimicrobial use.

Food safety received a score of 3 out of 5, while surveillance of zoonotic diseases was rated 4 out of 5.

These findings reflect the situation assessed in 2022 and should not be interpreted as an evaluation of Uzbekistan's capacities as of November 2026.

Nevertheless, they identify areas that required further strengthening.

Study Involving More Than 2,000 Patients

One important step in developing laboratory surveillance was the Proof of Principle (PoP) project, implemented with technical support from the World Health Organization's Regional Office for Europe and the Netherlands National Institute for Public Health and the Environment (RIVM).

The project aimed to improve the diagnosis of bloodstream infections and establish a foundation for a national sentinel surveillance system for antimicrobial resistance.

A total of 2,063 patients with suspected bloodstream infections were examined.

Positive blood cultures were obtained from 299 patients, representing 14.5% of those tested.

Among 1,190 male patients, 210 had positive blood cultures (17.6%). Among 873 female patients, 89 tested positive (10.2%).

The study also assessed antibiotic resistance among selected pathogens.

Among 13 Klebsiella pneumoniae isolates recovered from blood samples, resistance to cefotaxime and gentamicin reached 92.3% each, while resistance to ciprofloxacin was 77% and to amikacin 46%.

For imipenem, the combined proportion of resistant and intermediate-susceptibility isolates was 38.4%, while resistance to meropenem was 7.6%.

Among 33 Staphylococcus aureus isolates, resistance to cefoxitin, used as a marker of methicillin resistance, was 39%.

Resistance to erythromycin reached 42.4%, while resistance to clindamycin stood at 36.3%.

However, some of the sample sizes were small. For example, the findings for Klebsiella pneumoniae were based on just 13 isolates.

These percentages therefore cannot be interpreted as nationwide estimates of resistance to the antibiotics concerned.

More Than 1,000 E. coli Isolates Included in Surveillance Data

According to materials from the Center for Antimicrobial Resistance Studies, accumulated laboratory surveillance data include 1,101 isolates of Escherichia coli, 536 of Staphylococcus aureus, 367 of Klebsiella pneumoniae, and 129 of Pseudomonas aeruginosa.

The data also include 58 isolates of Streptococcus pneumoniae and 30 isolates of Acinetobacter spp.

The surveillance programme focuses on eight priority pathogens included in the CAESAR framework.

Notably, 93% of the Escherichia coli isolates were obtained from urine samples — 1,029 out of 1,101.

This distribution must be considered when interpreting the findings, as laboratory surveillance results depend on the characteristics of the patients examined and the types of clinical specimens collected.

The presentation also identifies the need to expand the network of pilot surveillance sites from five to ten, particularly by including healthcare facilities that perform larger numbers of blood culture tests.

Digitalization of Infectious Disease Surveillance

Digitalization has become another priority in strengthening epidemiological surveillance.

Since October 2025, Uzbekistan has been developing ISEMIZ, an electronic system for monitoring infectious diseases.

According to the information presented, the system covers 102 infectious diseases, while more than 1,000 specialists have received training with WHO support.

The development of digital infrastructure is intended to improve the timeliness of epidemiological data collection and analysis.

However, effective antimicrobial resistance surveillance requires more than electronic databases. It also depends on comparable laboratory results, standardized testing methods, and quality assurance.

The ability to integrate information from healthcare, veterinary, and environmental institutions is particularly important.

Why Monitoring Antibiotic Use Matters

The presentation also discussed a survey of public knowledge and practices conducted across eight districts of Tashkent.

The survey involved representatives of 159 pharmacies and 279 residents.

Researchers examined knowledge about antibiotics, attitudes toward their use for sore throats, runny noses, coughs, and fever, as well as the possibility of purchasing these medicines without medical supervision.

The findings highlight patient behavior and pharmacy dispensing practices as important areas for preventing antimicrobial resistance.

However, some percentages presented in the study were based on small subgroups. Accurate interpretation therefore requires clarification of the number of respondents who answered each question.

Other challenges identified include antibiotic use before hospitalization, inappropriate prescribing in certain clinical situations, irregular professional training, and difficulties in supplying laboratories with high-quality reagents.

The national action plan provides for improved prescription monitoring, collection of antibiotic consumption data, and implementation of antimicrobial stewardship programmes.

Uzbekistan's Priorities for 2027–2030

Further priorities for strengthening the national response to antimicrobial resistance include expanding laboratory surveillance, improving diagnostic quality, and enhancing data exchange.

Particular attention is proposed for integrating medical information systems, the WHONET laboratory platform, and environmental monitoring.

Strengthening veterinary surveillance and controlling antibiotic residues in food products remain important areas of work.

Proposed measures include monitoring veterinary drug residues in meat and milk, investigating bacterial resistance throughout the food chain, and tracking antimicrobial use in livestock production.

Other priorities include developing regional laboratories, training specialists in EUCAST standards, and strengthening cooperation between healthcare and veterinary institutions.

The priorities presented for 2027–2030 are proposals that require further coordination and agreement with the responsible government agencies.

From Individual Studies to an Integrated System

Uzbekistan already has experience in laboratory surveillance of antimicrobial resistance, international research projects, and infectious disease monitoring.

However, further efforts are needed to integrate fragmented data, expand laboratory testing coverage, and establish regular monitoring of antibiotic use.

Under the One Health approach, combating antimicrobial resistance is viewed as a shared responsibility of healthcare, veterinary services, food safety authorities, and environmental institutions.

Developing such an integrated system could improve infection prevention, strengthen the quality of healthcare, and support more effective use of public resources.

Kamila Fayzieva, exclusively for UzDaily

Astana, Kazakhstan

Kamila Fayzieva
Kamila Fayzieva

Kamila Fayzieva is a Researcher & Analyst specializing in Climate, Economy & Fintech Systems. She is a contributor to UzDaily.